期刊文献+

自噬在慢性髓细胞白血病中的研究进展 被引量:1

Research progress of autophagy in chronic myeloid leukemia
原文传递
导出
摘要 一线酪氨酸激酶抑制剂(TKI)给慢性髓细胞白血病(CML)的治疗带来了革命性进步。但长期应用TKI所带来的毒副作用、经济负担、CML干细胞的残留等问题,给TKI的临床应用带来了挑战。TKI的耐药问题也成为了目前CML研究中的热点。自噬是一种细胞面临营养缺乏或者应激状态时的自我保护机制。近年来越来越多的研究提示,自噬在CML细胞增殖、TKI耐药等过程中发挥重要作用。 Despite of taking a revolutionary progress to the treatment of chronic myeloid leukemia(CML),tyrosine kinase inhibitor(TKI)has raised a series of issues,such as relapse,drug-resistance,adverse effects and unbearable financial burden.It's recently been the highlight of CML research to prolong the overall survival of patients by regaining the sensitivity of TKI,as well as eliminating CML stem cells.It's been recently elucidated that autophagy,as a self-protected process against nutrients insufficiency or stress,participates in various pathophysiological activities.Autophagy plays both a pro-survival and pro-death role in tumorigenesis.Specific mechanism by which autophagy regulates CML cells needs to be explored in order to further improve the outcome of CML.Here,we make a comprehensive review on the molecular biologics of autophagy and its relations with CML.
出处 《临床血液学杂志》 CAS 2017年第1期76-79,共4页 Journal of Clinical Hematology
基金 台州市科技局资助项目(No:131KY14-03)
关键词 自噬 白血病 髓系 慢性 BCR-ABL 酪氨酸激酶抑制剂 autophagy chronic myeloid leukemia BCR-ABL tyrosine kinase inhibitor
  • 相关文献

同被引文献12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部